3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Multiple Myeloma
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Lung Neoplasms
2
Hematologic Neoplasms
2
Gastrointestinal Stromal Tumors
2
Advanced Malignancies
2
Solid Tumor
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Neoplasms
1
Melanoma
1
Liposarcoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Diseases
1
Carcinoma, Squamous Cell
1
Carcinoma, Large Cell
1
Interventions
Brentuximab Vedotin
20
Rituximab
10
pirtobrutinib
7
dacetuzumab
7
Doxorubicin
6
ruxolitinib
5
Vincristine
5
Prednisone
5
Lenalidomide
5
Cyclophosphamide
5
ponatinib
4
Imatinib Mesylate
4
Dexamethasone
4
Bendamustine Hydrochloride
4
Azacitidine
4
nilotinib
3
lintuzumab
3
Bortezomib
3
vosaroxin
2
venetoclax
2
spartalizumab
2
pomalidomide
2
ibrutinib
2
Rifampin
2
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
2
KW-2478
2
Ifosfamide
2
Gemcitabine
2
Etoposide
2
Dacarbazine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Hematologic Diseases
×
tanespimycin
×
Clear all
NCT00113204
2008-05-20
IPi-504-01
Infinity Pharmaceuticals, Inc.
Phase 1
Completed
18 enrolled